Aim The Assessment of Spondyloarthritis International Society Health Index (ASAS HI) Croatian version was used to assess health and functioning of patients with spondyloarthritis (SpA) covering aspects of physical, emotional and social functioning. Methods A cross sectional study was conducted at the Clinic for Internal Diseases Tuzla from January to June 2021. Inclusion criteria: fulfilled the ASAS diagnostic criteria for SpA. Exclusion criteria: failure to fulfil the diagnostic criteria, acute infection, the use of antibiotics in the past month, malignancy, associated disorders, psychiatric disorders, pregnancy, patient’s refusal to take part in the study. The Disease Activity Score with C reactive protein values (ASDAS-CRP) was assessed. Results Eighty three patients (43 male and 40 female) fulfilled the study criteria with median age of 54 years. The median value of ASDAS-CRP was 2.15, since ASAS HI had the median of 8 (interquartile range; IQR: 2-13) points. Patients with inactivity and with low disease activity had the ASAS HI median of 2 (IQR: 0-6) and 5 (IQR: 1-9) points, respectively. Significantly higher values of ASAS HI were found in patients with moderate and high disease activity, males (13.5 and 16) and females (13 and 14), respectively. The correlation between ASDAS-CRP and ASAS HI, (r=0.62; p<0.0009) was positive, statistically significant. However, the significant correlation between disease duration and ASAS HI values was not found (r=0.11; p=0.28). Conclusion The ASAS HI, Croatian version, is valid and reliable disease specific questionnaire for the assessment of health status in patients with SpA in the Bosnian speaking area.
Rudwaleit M, Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial apondyloarthritis (part II): validation and final selection. Vol. 68, Ann Rheum Dis. 2009. p. 777–83.
2.
Barkhodari A, Lee KE, Shen M, Shen B, Yao Q. Inflammatory bowel disease: focus on enteropathic arthritis and therapy. Vol. 3, Rheumatol Immunol Res. 2022. p. 69–76.
3.
Braun J, Baraliakos X, Buehring B, Kiltz U, Fruth M. Imaging of axial spondyloarthritis. New aspects and differential diagnoses. Vol. 36, Clin Exp Rheumatol. 2018. p. 35–42.
4.
Walsh HA, Magrey M. Clinical manifestations and diagnosis of axial spondyloarthritis. J Clin Rheumatol. 2021. p. 27 547-560.
5.
Strand V, Singh JA. Evaluation and management of the patient with suspected inflammatory spine disease. Vol. 92, Mayo Clin Proc. 2017. p. 555–64.
6.
Baysal O, Durmuş B, Ersoy Y, Altay Z, Senel K, Nas K, et al. Relationship between psychological status and disease activity and quality of life in ankylosing spondylitis. Vol. 31, Rheumatol Int. 2011. p. 795–800.
7.
Kilic G, Kilic E, Ogzocmen S. Realtionship between psychiatric status, self-reported outcome measures, and clinical parameters in axial spondyloarthritis. Vol. 93:e337, Medicine (Baltimore. 2014.
8.
Reddy KN, Sabu N, Raut A, Joag K, Patil P. Anxiety and depression among patients with axial spondyloarthritis. Vol. 9, Eur J Rheumatol. 2022. p. 8–13.
9.
Chimenti MS, Congigliaro P, Polistena B, Triggianese P, D’Antonio A, Neri B, et al. Observational study on the evaluation of quality of life in patients affected by enteropathic spondyloarthritis. Vol. 18, Musculokeletal Care. 2020. p. 527–34.
10.
Sağ S, Nas K, Sağ MS, Tekeoğlu İ, Kamanlı A. Relationship of work disability between the disease activity, depression and quality of life in patients with ankylosing spondylitis. Vol. 31, J Back Musculoskeletal Rehabil. 2018. p. 499–505.
11.
Kiltz U, Heijde D, Boonen A, Braun J. The ASAS Health Index (ASAS HI)- a new tool to assess the health status of patients with spondyloarthritis. Vol. 32, Clin Exp Rheumatol. 2014. p. 105–8.
12.
Kiltz U, Heijde D, Boonen A, Akkoc N, Bautista-Molano W, Burgos-Vargas R, et al. Measurement properties of the ASAS Health Index: results of a global study in patinets with axial and peripheral spondyloarthritis. Vol. 77, Ann Rheum Dis. 2018. p. 1311–7.
13.
Martindale J, Shukla R, Goodacre J. The impact of ankylosing spondylitis/axial spondyloarthritis on work productivity. Vol. 29, Best Pract Res Clin Rheumatol. 2015. p. 512–23.
14.
Kiltz U, Mau W, Repschläger U, Böhle E, Braun J. German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 9 International classification of functioning, disability and health (ICF. Vol. 73, Z Rheumatol. 2014. p. 104–8.
15.
Rudwaleit M. New approaches of diagnosis and classification of axial and peripheral spondyloarthritis. Vol. 22, Curr opin Rheumatol. 2010. p. 375–80.
16.
Machado PM, Landewé R, Heijde D. Assessment of SpondyloArthritis international Society (ASAS. Vol. 77, Ann Rheum Dis. 2018. p. 1539–40.
17.
Boel A, Molto A, Heijde D, Ciurea A, Dougados M, Gensler LS, et al. Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS.
18.
axial spondyloarthritis criteria? Results from eight cohorts. Vol. 78, Ann Rheum Dis. 2019. p. 1545–9.
19.
Linden S, HA V, A C. Evaluation of diagnostic criteris for ankylosing spondylitis. A proposal for modification of the New York criteria. Vol. 27, Arthritis Rheum. 1984. p. 361–8.
20.
Ward MM. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Vol. 12, Arthritis Care Res. 1999. p. 247–55.
21.
Jones A, Harrison N, Jones T, Rees JD, Bennet AN. Time of diagnosis of axial spondylarthritis in clinical practice: signs of improving awareness? Vol. 53, Rheumatology (Oxford. 2014. p. 2126–7.
22.
Jovani V, Blasco-Blasco M, Ruiz-Cantero MT, Pascual E. Understanding how the diagnostic delay of spondyloarthritis differs between women and men: a systematic review and metaanalysis. Vol. 44, J Rheumatol. 2017. p. 174–83.
23.
Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, et al. The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study. Vol. 71, Ann Rheum Dis. 2012. p. 1207–11.
24.
Rusman T, Vollenhoven RF, Horst-Bruinsma IE. Gender Differences in Axial Spondyloarthritis: Women Are Not So Lucky. Vol. 20, Curr Rheumatol Rep. 2018.
25.
Carlo M, V L, M C, F S. Clinimetric properties of the ASAS health index in a cohort of Italian patients with axial spondyloarthritis. Vol. 14, Healt Qual Life Outcomes. 2016.
26.
Bautista-Molano W, Landewé RBM, Kiltz U, ValleOñate van der H, D. Validation and reliability of translation of the ASAS Healt Index in a ColombianSpanish-speaking population with spondyloarthritis. Vol. 37, Clin Rheumatol. 2018. p. 3063–8.
27.
Chen HH, Lin CT, Chen YM, Lai KL, Hsieh TY, Hung WT, et al. Gender difference in ASAS HI among patients with ankylosing spondylitis. Vol. 15:e0235678, PLoS One. 2020.
28.
Carlo M, V L, Matteo A, M C, F S. Defining functioning categories in axial spondyloarthritis: the role of the ASAS Health Index. Vol. 37, Rheumatol Int. 2017. p. 713–8.
29.
Akgul O, Bodur H, Ataman S, Yurdakul FG, Capkin E, Gurer G, et al. Clinical performance of ASAS Health index in patients with ankylosing spondylitis and non radiographic axial spondyloarthritis: real-world evidence from Multicenter Nationwide Registry. Vol. 40, Rheumatol Int. 2020. p. 1793–801.
30.
Kiltz U, Braun J. Assessments of functioning in patients with axial spondyloarthritis. Vol. 27, J Rheum Dis. 2020. p. 22–9.
31.
Garret S, Jenkison T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity Index. Vol. 21, J Rheumatol. 1944. p. 2286–91.
32.
Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicenter trial. Vol. 359, Lancet. 2002. p. 1187–93.
33.
Essers I, Boonen A, Busch M, Heijde D, Keszei AP, Landewé R, et al. Fluctuations in patient reported disease activity, pain and global being in patients with ankylosing spondylitis. Vol. 55, Rheumatology (Oxford. 2016. p. 2014–22.
34.
Santos-Faria D, Dougados M, Gossec L, Perrot S, Moltö A. Evaluation of the performance of extreme patient-reported outcomes as surrogate markers for fibromyalgia in axial spondyloarthritis. Vol. 39, Rheumatol Int. 2019. p. 141–6.
35.
Weely SFE, J D, MPM S, Denderen JC, MT N, BAC D, et al. Objective evaluation of physical functioning after tumor necrosis factor inhibitory therapy in patients with ankylosing spondylitis: a selection of 3 feasible performance-based tests. Vol. 42, J Rheumatol. 2015. p. 623–9.
36.
Garrido-Cumbrera M, Delgado-Domínguez CJ, Gálvez-Ruiz D, Mur CB, Navarro-Compán AWG. The Effect of Axial Spondyloarthritis on Mental Health: Results from the Atlas. Vol. 46, J Rheumatol. 2019. p. 1284–9.
37.
Kiltz U, Ahomaa EP, Weely SFE, Kiefer D, Bühring B, Baraliakos X, et al. Clinically relevant deficits in performance tests in patients with axial spondyloarthritis. Vol. 50, J Rheumatol. 2023. p. 351–8.
38.
Booned A, Chorus A, Miedema H, Heijde D, Tempel H, Linden S. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch Patients. Vol. 60, Ann Rheum Dis. 2001. p. 353–8.
39.
Ariza-Ariza R, Hernandez-Cruz B, Navarro-Sarabia F. Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis. Vol. 49, Arthritis Rheum. 2003. p. 483–7.
40.
Choi JH, Kim TJ, Shin K, Choi CB, Kim JH, Kim SH, et al. The reliability and validity of a Korean translation of the ASAS health index and environmental factors in Korean patients with axial spondyloarthritis. Vol. 29, J Korean Med sci. 2014. p. 334–7.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
